The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman

Oncology Institute, Inc.

Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.
Daniel Virnich, current President, appointed CEO effective June 30, 2023.
Hively receives salary continuation, COBRA premiums for 12 months, and 50% of 2023 annual bonus at Board discretion.
All unvested restricted stock units vest through June 30, 2024 per existing vesting schedules.
Transition was not the result of any disagreement with the Company.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Brad Hively

Vice Chair of the Board

TOI · Oncology Institute, Inc.

Effective: 2023-06-30
Successor: Daniel Virnich
Filed: June 14, 2023, 7:59 PM ET

Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.

Appointed

Daniel Virnich

Chief Executive Officer

TOI · Oncology Institute, Inc.

Effective: 2023-06-30
Filed: June 14, 2023, 7:59 PM ET

the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brad Hively changed role as Vice Chair of the Board at Oncology Institute, Inc..

Action: transitioned
Role: Vice Chair of the Board

Exact text from the filing

Brad Hively will transition from his role as Chief Executive Officer of The Oncology Institute, Inc. (the “Company”) to Vice Chair of the Board of Directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Virnich was appointed as Chief Executive Officer at Oncology Institute, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board appointed Daniel Virnich, the Company’s current President, as Chief Executive Officer effective as of June 30, 2023

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001799191-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.